Hematologic Oncology

Expert oncologists highlight challenges in the setting of TP53-mutated AML and consider appropriate treatment strategies.

The addition of vedolizumab added to standard prophylaxis following unrelated allogeneic hematopoietic stem cell transplantation was superior to placebo at preventing lower gastrointestinal acute graft-vs-host disease.

Treatment with the cellular therapy Orca-T produced an improved graft-vs-host-disease and relapse-free survival rate in patients with high-risk myelodysplastic syndrome or acute leukemias.

Yago L. Nieto, MD, PhD, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from a phase 2 trial investigating panobinostat (Farydak), gemcitabine, busulfan, and melphalan plus autologous stem cell transplant (ASCT) in patients with high-risk or relapsed/refractory multiple myeloma.

Samer A. Srour, MB ChB, MS, discusses findings with Orca-Q, an investigational therapy consisting of enriched CD34+ stem cells plus T-cell subsets, in patients with high-risk hematologic malignancies eligible for myeloablative conditioning and allogeneic stem cell transplant.

Because of an economic burden on the healthcare system occurring through the per-patient cost of allogeneic hematopoietic cell transplant, novel treatments to replace transplant and prevent graft-vs-host disease are necessary.

A study did not find a correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib for the treatment of patients 2 years of age and younger with graft-vs-host disease.

Orca-Q when using myeloablative conditioning with only tacrolimus monotherapy in the haploidentical stem cell transplant setting had acceptable safety and resulted in encouraging outcomes for patients with high-risk hematologic malignancies.

Checkpoint inhibitor–based salvage regimens significantly reduced the likelihood that patients with relapsed/refractory classic Hodgkin lymphoma undergoing transplant would need further salvage therapy vs conventional salvage regimens.

Orca-T produced a 100% overall survival rate in 8 patients with hematologic malignancies who received an allogeneic hematopoietic stem cell transplant with 7/8 non-permissive HLA mismatched donors.

Matthew Frank, MD, PhD, discusses findings from a single-institution phase 1 trial investigating autologous CAR T cells targeting CD22 in adults with large B-cell lymphoma, including those who relapse after or are refractory to CD19-directed CAR T-cell therapy.

Experts share their insights and advice on how to best communicate with patients who are actively dealing with acute or chronic GvHD.

A look into the future of chronic GvHD and which treatment options patients the panel is most excited about.

Mayur Narkhede, MD, discusses findings from a pre-planned interim analysis of a phase 2 trial investigating siltuximab for the treatment of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome related to CAR T-cell therapy in adult patients with hematologic malignancies.

Brexucabtagene autoleucel demonstrated a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia regardless of prior lines of treatment or exposure to blinatumomab or allogeneic stem cell transplant, according to data from subgroup analyses of the ZUMA-3 trial.

Drs Flinn, Lamanna, Brown, and Tam discuss the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

The fully-human scFv CD19-targeted CAR T-cell therapy JCAR021 elicited durable responses but with a high rate of neurotoxicity when administered at a dose of 7 x 106 cells/kg in patients with relapsed or refractory large B-cell lymphoma, according to data from a phase 1/2 trial.

An independent data monitoring committee has recommended that a phase 3 trial evaluating uproleselan plus chemotherapy for patients with relapsed/refractory acute myeloid leukemia should continue to the planned overall survival event trigger.

The panelists discuss Dr Cluzeau’s presented case, emphasizing the importance of pathology reporting, and expand upon approaches to second-line treatment selection for patients with MDS-RS.

Dr Cluzeau introduces a second patient case of lower-risk MDS-RS with an SF3B1 mutation and symptomatic anemia, who received a first-line erythropoiesis-stimulating agent (ESA) and second-line luspatercept.

The primary end point of the phase 3 PhALLCON study was met as first-line ponatinib plus reduced-intensity chemotherapy outperformed imatinib for the treatment of patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Advances in the development of bispecific antibodies have demonstrated response rates close to or surpassing those of other agents in development, offering investigators an avenue to pursue phase 3 studies such as EPCORE DLBCL-1 to challenge standard of care with the CD3 × CD20 agent, epcoritamab in diffuse large B-cell lymphoma.

Amer Zeidan, MBBS, and Rami Komrokji, MD, offer closing remarks on recent advances in MF and MDS, and look towards the future of treatment.

Comprehensive discussion on the emergence of CPX-351 as a first-line treatment option for patients with acute myeloid leukemia.

Expert perspective on the role of a pharmacist in managing patients with identified tumor lysis syndrome.

Shared insight on IDH-mutated acute myeloid leukemia and appropriate first-line treatment options in this setting.

Anthony Perissinotti, PharmD, BCOP, highlights associated risk for tumor lysis syndrome and identifies signs and symptoms.

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.